Laurus Labs Limited (LAURUSLABS) - Total Liabilities
Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has total liabilities worth Rs44.82 Billion INR (≈ $484.68 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Laurus Labs Limited to see how much of total assets are deployed in long-term investments.
Laurus Labs Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how Laurus Labs Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LAURUSLABS total asset value.
Laurus Labs Limited Competitors by Total Liabilities
The table below lists competitors of Laurus Labs Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BJs Wholesale Club Holdings Inc
NYSE:BJ
|
USA | $5.80 Billion |
|
Hero MotoCorp Limited
NSE:HEROMOTOCO
|
India | Rs116.42 Billion |
|
Astra International Tbk
JK:ASII
|
Indonesia | Rp209.04 Trillion |
|
Guidewire Software Inc
NYSE:GWRE
|
USA | $1.18 Billion |
|
S-Oil Corp
KO:010950
|
Korea | ₩17.67 Trillion |
|
Fidelity National Financial Inc
NYSE:FNF
|
USA | $105.72 Billion |
|
MILLICOM INTL CELL. DL15
F:M4M1
|
Germany | €13.63 Billion |
|
Metso Oyj
HE:METSO
|
Finland | €4.81 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Laurus Labs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Laurus Labs Limited net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.02 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Laurus Labs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Laurus Labs Limited (2013–2025)
The table below shows the annual total liabilities of Laurus Labs Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs47.33 Billion ≈ $511.86 Million |
+10.81% |
| 2024-03-31 | Rs42.71 Billion ≈ $461.94 Million |
+18.27% |
| 2023-03-31 | Rs36.12 Billion ≈ $390.60 Million |
+0.08% |
| 2022-03-31 | Rs36.09 Billion ≈ $390.30 Million |
+14.57% |
| 2021-03-31 | Rs31.50 Billion ≈ $340.66 Million |
+59.05% |
| 2020-03-31 | Rs19.81 Billion ≈ $214.19 Million |
+11.72% |
| 2019-03-31 | Rs17.73 Billion ≈ $191.72 Million |
+15.56% |
| 2018-03-31 | Rs15.34 Billion ≈ $165.91 Million |
+15.96% |
| 2017-03-31 | Rs13.23 Billion ≈ $143.07 Million |
-8.84% |
| 2016-03-31 | Rs14.51 Billion ≈ $156.94 Million |
+29.36% |
| 2015-03-31 | Rs11.22 Billion ≈ $121.32 Million |
+22.63% |
| 2014-03-31 | Rs9.15 Billion ≈ $98.93 Million |
+105.95% |
| 2013-03-31 | Rs4.44 Billion ≈ $48.04 Million |
-- |
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more